← Back to Search

300 mg Cannabidiol (CBD) oil for Cognitive Impairment

Phase 2
Waitlist Available
Led By Toni Marie Rudisill, MS, PhD
Research Sponsored by West Virginia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1) the participant must be currently enrolled as a WVU student, 2) be 18-30 years of age at time of study, 3) have a current drivers' license issued from any state in the United States, 4) has driven at least once in the past 30 days 5) is able to speak and read English, 6) is willing to be randomized and comply with study requirements including a urine drug test on the day they consent to participate in the experiment and complete a test drive to ensure the absence of simulation sickness, 7) not currently taking any daily prescription medications other than birth control, 8) have not been diagnosed with any serious chronic disease by a licensed healthcare provider (including but not limited to Alzheimer's and related dementias, Parkinson's disease or other neurodegenerative disorder, major depressive or anxiety disorder, schizophrenia or other serious mental illness, arrhythmias, cataracts, glaucoma, chronic obstructive pulmonary disease, diabetes, epilepsy, sleep apnea, and fibromyalgia), and 9) has an individual able to drive them home after testing or is willing to be driven home by study staff after testing completion.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1.5 hour post intervention
Awards & highlights

Summary

A randomized, parallel-group, double-blind, exploratory two-arm trial to assess the effects of CBD on driving ability along with changes in psychological status (i.e. mood, drowsiness, sedation) and cognitive function. Forty healthy West Virginia University (WVU) students will be allocated and randomized to receive: (1) 300 mg of pure CBD oil or (N=20) (2) placebo matched in appearance and taste (N=20). After consuming the study drug, each individual will participate in a 25-35-minute driving simulation and their driving performance measured. To assess changes in psychological status (i.e. mood, drowsiness, sedation) and drug impairment-related cognitive function, the Visual Analog Mood Scale, Stanford Sleepiness Scale , Digital Symbol Substitution Test, Trail Making Test Part A and B, Psychomotor Vigilance Test, and Simple Reaction Time test will also be administered to participants at baseline (prior to study drug consumption) and following completion of the driving simulation test. The entire protocol will be completed in one day and should take 4-4.5 hours to complete for each participant.

Eligible Conditions
  • Cognitive Impairment
  • Sedation Complication
  • Depression
  • Driving Performance

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1.5 hour post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1.5 hour post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Driving Performance - Brake Reaction Time
Driving Performance - Lateral Position in Lane
Driving Performance - Number of Collisions.
+2 more
Secondary outcome measures
Change in Baseline DSST
Change in Baseline PVT
Change in Baseline SRT for Sound #1
+6 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 300 mg Cannabidiol (CBD) oilActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

West Virginia UniversityLead Sponsor
181 Previous Clinical Trials
63,671 Total Patients Enrolled
Toni Marie Rudisill, MS, PhDPrincipal Investigator - West Virginia University
West Virginia University
~9 spots leftby Sep 2025